Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Activation of thyroid hormone receptor‐β improved disease activity and metabolism independent of body weight in a mouse model of non‐alcoholic steatohepatitis and fibrosis
Aimo Kannt, Paulus Wohlfart, Andreas Nygaard Madsen, et al.
British Journal of Pharmacology (2021) Vol. 178, Iss. 12, pp. 2412-2423
Open Access | Times Cited: 78

Showing 1-25 of 78 citing articles:

Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)
Xiaohan Xu, Kyle L. Poulsen, Lijuan Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 207
Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways
Olufunto O. Badmus, Sarah A. Hillhouse, Christopher D. Anderson, et al.
Clinical Science (2022) Vol. 136, Iss. 18, pp. 1347-1366
Open Access | Times Cited: 179
Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
Rong Li, Junyan Zou, Wei Ran, et al.
Frontiers in Endocrinology (2023) Vol. 13
Open Access | Times Cited: 156
Resmetirom: First Approval
Susan J. Keam
Drugs (2024) Vol. 84, Iss. 6, pp. 729-735
Closed Access | Times Cited: 93
Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease
Tingying Jiao, Yuandi Ma, Xiaozhen Guo, et al.
Acta Pharmacologica Sinica (2022) Vol. 43, Iss. 5, pp. 1103-1119
Open Access | Times Cited: 77
The first MASH drug therapy on the horizon: Current perspectives of resmetirom
Salvatore Petta, Giovanni Targher, Stefano Romeo, et al.
Liver International (2024) Vol. 44, Iss. 7, pp. 1526-1536
Open Access | Times Cited: 64
Thyromimetics and MASLD: Unveiling the Novel Molecules Beyond Resmetirom
Devaraj Ezhilarasan
Journal of Gastroenterology and Hepatology (2025)
Closed Access | Times Cited: 2
Resmetirom and thyroid hormone receptor‐targeted treatment for metabolic dysfunction‐associated steatotic liver disease (MASLD)
Chang‐Hai Liu, Qingchun Zeng, Tianxiao Hu, et al.
Portal hypertension & cirrhosis (2025)
Open Access | Times Cited: 2
NAFLD and thyroid function: pathophysiological and therapeutic considerations
Erifili Hatziagelaki, Stavroula Α. Paschou, Martin Schön, et al.
Trends in Endocrinology and Metabolism (2022) Vol. 33, Iss. 11, pp. 755-768
Open Access | Times Cited: 46
Mouse models of nonalcoholic fatty liver disease (NAFLD): pathomechanisms and pharmacotherapies
Tingyu Fang, Hua Wang, Xiaoyue Pan, et al.
International Journal of Biological Sciences (2022) Vol. 18, Iss. 15, pp. 5681-5697
Open Access | Times Cited: 42
Obesity, non-alcoholic fatty liver disease and hepatocellular carcinoma: current status and therapeutic targets
Yinshuang Chen, Weipeng Wang, Maria P. Morgan, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 31
Thyroid hormone receptor-beta agonists: new MASLD therapies on the horizon
Christopher D. Byrne, Giovanni Targher, Herbert Tilg
Gut (2024), pp. gutjnl-330596
Open Access | Times Cited: 14
Resmetirom's approval: Highlighting the need for comprehensive approaches in NASH therapeutics
Salah Abdalrazak Alshehade
Clinics and Research in Hepatology and Gastroenterology (2024) Vol. 48, Iss. 7, pp. 102377-102377
Closed Access | Times Cited: 13
Intrahepatic hypothyroidism in MASLD: Role of liver-specific thyromimetics including resmetirom
Mohammad Shafi Kuchay, Scott Isaacs, Anoop Misra
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2024) Vol. 18, Iss. 5, pp. 103034-103034
Closed Access | Times Cited: 12
Resmetirom and Metabolic Dysfunction-Associated Steatohepatitis: Perspectives on Multidisciplinary Management from Global Healthcare Professionals
K.F. Au, Ming‐Hua Zheng, Wei‐Jei Lee, et al.
Current Obesity Reports (2024) Vol. 13, Iss. 4, pp. 818-830
Closed Access | Times Cited: 9
Hypothyroidism/subclinical hypothyroidism and metabolic dysfunction-associated steatotic liver disease: advances in mechanism and treatment
Sicheng Pu, Binbin Zhao, Yuxuan Jiang, et al.
Lipids in Health and Disease (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Updates on novel pharmacotherapeutics for the treatment of nonalcoholic steatohepatitis
Yong‐Yu Yang, Li Xie, Ning‐Ping Zhang, et al.
Acta Pharmacologica Sinica (2022) Vol. 43, Iss. 5, pp. 1180-1190
Open Access | Times Cited: 37
Thyroid hormones as a disease modifier and therapeutic target in nonalcoholic steatohepatitis
Eva K. Wirth, Tobias Puengel, Joachim Spranger, et al.
Expert Review of Endocrinology & Metabolism (2022) Vol. 17, Iss. 5, pp. 425-434
Closed Access | Times Cited: 35
Shedding light on non-alcoholic fatty liver disease: Pathogenesis, molecular mechanisms, models, and emerging therapeutics
Rhema Khairnar, Md Asrarul Islam, Joshua S. Fleishman, et al.
Life Sciences (2022) Vol. 312, pp. 121185-121185
Closed Access | Times Cited: 31
Discovery of a natural small-molecule AMP-activated kinase activator that alleviates nonalcoholic steatohepatitis
Jin Chen, Xu Li, Xueqing Zhang, et al.
Marine Life Science & Technology (2023) Vol. 5, Iss. 2, pp. 196-210
Open Access | Times Cited: 20
Discovery of Highly Potent and Selective Thyroid Hormone Receptor β Agonists for the Treatment of Nonalcoholic Steatohepatitis
Liuyu Hu, Yipei Gu, Ju Liang, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 5, pp. 3284-3300
Closed Access | Times Cited: 18
FXR and NASH: an avenue for tissue-specific regulation
Zakiyah Henry, Vik Meadows, Grace L. Guo
Hepatology Communications (2023) Vol. 7, Iss. 5
Open Access | Times Cited: 18
MASLD treatment—a shift in the paradigm is imminent
Mariana Verdelho Machado
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 18
Recent advances in age-related metabolic dysfunction-associated steatotic liver disease
Qianjun He, Yifei Li, Ling-Tong Zhao, et al.
World Journal of Gastroenterology (2024) Vol. 30, Iss. 7, pp. 652-662
Open Access | Times Cited: 7
The gut-liver axis: emerging mechanisms and therapeutic approaches for nonalcoholic fatty liver disease and type 2 diabetes mellitus
Monika Bhardwaj, Papiya Mitra Mazumder
Naunyn-Schmiedeberg s Archives of Pharmacology (2024)
Closed Access | Times Cited: 7
Page 1 - Next Page

Scroll to top